MicroRNAs and their antagonists as novel therapeutics

From Nucleic Acids Sequences to Molecular Medicine

Volumn , Issue , 2012, Pages 503-523

  Vinther, Jeppe ^a   Rukov, Jakob Lewin ^a,b   Shomron, Noam ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

MicroRNA; MicroRNA antagonism; MicroRNA delivery; RNA drugs; Therapeutics

Indexed keywords

EID: 84973144306     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-27426-8_20     Document Type: Chapter

References (93)

1. Anand S, Majeti BK, Acevedo LM et al (2010) MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med 16:909-914
2. Aqeilan RI, Calin GA, Croce CM (2009) miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 17:215-220
3. Baek D, Villen J, Shin C et al (2008) The impact of microRNAs on protein output. Nature 455:64-71
4. Bennett CF, Swayze EE (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50:259-293
5. Bostjancic E, Zidar N, Stajer D et al (2010) MicroRNAs miR-1, miR-133a, miR-133b and miR- 208 are dysregulated in human myocardial infarction. Cardiology 115:163-169
6. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857-866
7. Calin GA, Dumitru CD, Shimizu M et al (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99:15524-15529
8. Callis TE, Pandya K, Seok HY et al (2009) MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 119:2772-2786
9. Cheng Y, Zhang C (2010) MicroRNA-21 in cardiovascular disease. J Cardiovasc Transl Res 3:251-255
10. Cheng Y, Zhu P, Yang J et al (2010) Ischaemic preconditioning-regulated miR-21 protects heart against ischaemia/reperfusion injury via anti-apoptosis through its target PDCD4. Cardiovasc Res 87:431-439
11. Chi SW, Zang JB, Mele A et al (2009) Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 460:479-486
12. Chiang HR, Schoenfeld LW, Ruby JG et al (2010) Mammalian microRNAs: experimental evaluation of novel and previously annotated genes. Genes Dev 24:992-1009
13. Choi WY, Giraldez AJ, Schier AF (2007) Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430. Science 318:271-274
14. Davis S, Lollo B, Freier S et al (2006) Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res 34:2294-2304
15. Davis S, Propp S, Freier SM et al (2009) Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res 37:70-77
16. Djuranovic S, Nahvi A, Green R (2011) A parsimonious model for gene regulation by miRNAs. Science 331:550-553
17. Dong S, Cheng Y, Yang J et al (2009) MicroRNA expression signature and the role of microRNA- 21 in the early phase of acute myocardial infarction. J Biol Chem 284:29514-29525
18. Dorn GW II (2011) MicroRNAs in cardiac disease. Transl Res 157:226-235
19. Ebert MS, Neilson JR, Sharp PA (2007) MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Met 4:721-726
20. Ebert MS, Sharp PA (2010) MicroRNA sponges: progress and possibilities. RNA 16:2043-2050
21. Elmen J, Lindow M, Schutz S et al (2008a) LNA-mediated microRNA silencing in non-human primates. Nature 452:896-899
22. Elmen J, Lindow M, Silahtaroglu A et al (2008b) Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 36:1153-1162
23. Esau C, Davis S, Murray SF et al (2006) miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3:87-98
24. Filipowicz W, Jaskiewicz L, Kolb FA et al (2005) Post-transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struct Biol 15:331-341
25. Friedman RC, Farh KK, Burge CB et al (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19:92-105
26. Garzon R, Marcucci G, Croce CM (2010) Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9:775-789
27. Greenberger LM, Horak ID, Filpula D et al (2008) A RNA antagonist of hypoxia-inducible factor- lalpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 7:3598-3608
28. Gregory RI, Chendrimada TP, Cooch N et al (2005) Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 123:631-640
29. Gregory RI, K-p Y, Amuthan G et al (2004) The microprocessor complex mediates the genesis of microRNAs. Nature 432:235-240
30. Griffiths-Jones S (2010) miRBase: microRNA sequences and annotation. Current Protocols in Bioinformatics DOI: 10.1002/0471250953.bi1209s29
31. Grimson A, Farh KK-H, Johnston WK et al (2007) MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 27:91-105
32. Guil S, Caceres JF (2007) The multifunctional RNA-binding protein hnRNP A1 is required for processing of miR-18a. Nat Struct Mol Biol 14:591-596
33. Guo H, Ingolia NT, Weissman JS et al (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466:835-840
34. Hu Z, Chen X, Zhao Y et al (2010) Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 28:1721-1726
35. Hutvagner G, Simard MJ, Mello CC et al (2004) Sequence-specific inhibition of small RNA function. PLoS Biol 2:E98
36. Hwang-Verslues WW, Chang PH, Wei PC et al (2011) miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1. Oncogene 30:2463-2474
37. Jopling CL, Yi M, Lancaster AM et al (2005) Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309:1577-1581
38. Koller E, Vincent TM, Chappell A et al (2011) Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res 39:4795-4807
39. Kota J, Chivukula RR, O’Donnell KA et al (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137:1005-1017
40. Krutzfeldt J, Kuwajima S, Braich R et al (2007) Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res 35:2885-2892
41. Krutzfeldt J, Rajewsky N, Braich R et al (2005) Silencing of microRNAs in vivo with’antagomirs’. Nature 438:685-689
42. Kurreck J, Wyszko E, Gillen C et al (2002) Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res 30:1911-1918
43. Kutay H, Bai S, Datta J et al (2006) Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 99:671-678
44. Lanford RE, Hildebrandt-Eriksen ES, Petri A et al (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327:198-201
45. Lares MR, Rossi JJ, Ouellet DL (2010) RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol 28:570-579
46. Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843-854
47. Lennox KA, Behlke MA (2010) A direct comparison of anti-microRNA oligonucleotide potency. PharmRes 27:1788-1799
48. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15-20
49. Lewis BP, Shih IH, Jones-Rhoades MW et al (2003) Prediction of mammalian microRNA targets. Cell 115:787-798
50. Li Q-J, Chau J, Ebert PJR et al (2007) miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 129:147-161
51. Lim LP, Lau NC, Garrett-Engele P et al (2005) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433:769-773
52. Ling HY, Ou HS, Feng SD et al (2009) Changes in microRNA profile and effects of miR-320 in insulin-resistant 3T3-L1 adipocytes. Clin Exp Pharmacol Physiol 36:E32-E39
53. Liu N, Olson EN (2010) MicroRNA regulatory networks in cardiovascular development. Dev Cell 18:510-525
54. Lu J, Getz G, Miska EA et al (2005) MicroRNA expression profiles classify human cancers. Nature 435:834-838
55. Meister G (2004) Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA 10:544-550
56. Michlewski G, Guil S, Semple CA et al (2008) Posttranscriptional regulation of miRNAs harboring conserved terminal loops. Mol Cell 32:383-393
57. Muralidhar B, Winder D, Murray M et al (2011) Functional evidence that Drosha overexpression in cervical squamous cell carcinoma affects cell phenotype and microRNA profiles. J Pathol 224:496-507
58. Nicoloso MS, Sun H, Spizzo R et al (2010) Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res 70:2789-2798
59. Nielsen CB, Shomron N, Sandberg R et al (2007) Determinants of targeting by endogenous and exogenous microRNAs and siRNAs. RNA 13:1894-1910
60. O’Connell RM, Rao DS, Chaudhuri AA et al (2008) Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 205:585-594
61. O’Connell RM, Taganov KD, Boldin MP et al (2007) MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 104:1604-1609
62. O’Day E, Lal A (2010) MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 12:201
63. Obad S, dos Santos CO, Petri A et al (2011) Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 43:371-378
64. Orom UA, Kauppinen S, Lund AH (2006) LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 372:137-141
65. Paddison PJ, Caudy AA, Bernstein E et al (2002) Short hairpin RNAs (shRNAs) induce sequence- specific silencing in mammalian cells. Genes Dev 16:948-958
66. Patrick DM, Zhang CC, Tao Y et al (2010) Defective erythroid differentiation in miR-451 mutant mice mediated by 14-3-3zeta. Genes Dev 24:1614-1619
67. Provost P (2010) MicroRNAs as a molecular basis for mental retardation, Alzheimer’s and prion diseases. Brain Res 1338:58-66
68. Qi L, Bart J, Tan L et al (2009) Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer 9:163
69. Rayner KJ, Sheedy FJ, Esau CC et al (2011) Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 121:2921-2931
70. Rukov JL, Shomron N (2011) MicroRNA pharmacogenomics: post-transcriptional regulation of drug response. Trends Mol Med 17:412-423
71. Satoh M, Minami Y, Takahashi Y et al (2010) Expression of microRNA-208 is associated with adverse clinical outcomes in human dilated cardiomyopathy. J Card Fail 16:404-410
72. Selbach M, Schwanhausser B, Thierfelder N et al (2008) Widespread changes in protein synthesis induced by microRNAs. Nature 455:58-63
73. Selcuklu SD, Donoghue MT, Spillane C (2009) miR-21 as a key regulator of oncogenic processes. Biochem Soc Trans 37:918-925
74. Shomron N, Golan D, Hornstein E (2009) An evolutionary perspective of animal microRNAs and their targets. J Biomed Biotechnol 2009:594-738
75. Stefani G, Slack FJ (2008) Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 9:219-230
76. Stein CA, Hansen JB, Lai J et al (2010) Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res 38:e3
77. Takeshita F, Patrawala L, Osaki M et al (2010) Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 18:181-187
78. Terao M, Fratelli M, Kurosaki M et al (2011) Induction of miR-21 by retinoic acid in estrogen receptor-positive breast carcinoma cells. J Biol Chem 286:4027-4042
79. Thum T, Gross C, Fiedler J et al (2008) MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456:980-984
80. Trajkovski M, Hausser J, Soutschek J et al (2011) MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474:649-653
81. Trang P, Wiggins JF, Daige CL et al (2011) Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 19:1116-1122
82. van Rooij E, Quiat D, Johnson BA et al (2009) A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell 17:662-673
83. van Rooij E, Sutherland LB, Liu N et al (2006) A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 103:18255-18260
84. van Rooij E, Sutherland LB, Qi X et al (2007) Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316:575-579
85. van Rooij E, Sutherland LB, Thatcher JE et al (2008) Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 105:13027-13032
86. Wang H, Garzon R, Sun H et al (2008) NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 14:369-381
87. Wightman B, Ha I, Ruvkun G (1993) Posttranscriptional regulation of the heterochronic gene lin- 14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75:855-862
88. Xiao J, Yang B, Lin H et al (2007) Novel approaches for gene-specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4. J Cell Phys 212:285-292
89. Yi R, Poy MN, Stoffel M, Fuchs E (2008) A skin microRNA promotes differentiation by repressing’sternness’. Nature 452:225-229
90. Yin C, Salloum FN, Kukreja RC (2009) A novel role of microRNA in late preconditioning. Circ Res 104:572-575
91. Yu RZ, Kim TW, Hong A et al (2007) Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipo- protein B-100. Drug Metab Dispos 35:460-468
92. Zeng Y, Wagner EJ, Cullen BR (2002) Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell 9:1327-1333
93. Zeng Y, Yi R, Cullen BR (2003) MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci USA 100:9779-9784